drugset / Trial / NCT00385359

A Pilot Efficacy Study of Inhaled Albuterol Delivered With Akita Breath Control

NCT00385359

Phase 4 Unknown 10 enrolled University Health Network, Toronto
RandomizedCrossoverOpen-labelTreatment

Summary

Albuterol (salbutamol) is a widely used asthma medication but is associated with undesirable side effects such as shakiness and increased heart rate. Targeted delivery of albuterol to area of lungs where it has most effect would require a lower total dose to produce the same beneficial effects while reducing the side effects. It is anticipated that only 1/13th to 1/25th of the standard nebulized dose of albuterol will be required to attain same bronchodilator response as a standard nebulizer treatment as determined by lung function measurement and that the reduced dose will significantly reduce side effects as determined by hand tremor and heart rate.

Timeline

Start
2006-10
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Salbutamol Unknown Inhaled

Indications